DS18 Comparative analysis of real-world cost and carbon footprint of cutaneous squamous cell carcinoma follow-up pathways
DS18 皮膚有棘細胞癌のフォローアップ経路における実世界のコストとカーボンフットプリントの比較分析 (AI 翻訳)
Kate Price, William Tarn-Chapman, Simon Tso
🤖 gxceed AI 要約
日本語
皮膚有棘細胞癌（SCC）のフォローアップに伴う経済的コストと炭素排出量を実データで推定した初の研究。50患者の診療記録を分析し、リスク層別に中央値で668ポンド/80.9kgCO2e（低リスク）から1111ポンド/187kgCO2e（高リスク）と試算。2020年ガイドライン改定後も有意な変化は見られなかった。
English
This first real-world study estimates financial cost and carbon footprint of SCC follow-up pathways. Analyzing 50 patients, median cost and emissions range from £668/80.9kgCO2e (low risk) to £1111/187kgCO2e (high risk). The 2020 BAD guideline update showed no significant impact.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本の医療分野でもカーボンフットプリント算定の必要性が高まっており、本手法は診療ガイドラインと環境負荷の関係を定量化する参考例となる。ただし、日本独自の診療報酬体系や排出係数に合わせた調整が必要。
In the global GX context
This study presents a methodological template for integrating carbon accounting into clinical pathway analysis, relevant to global healthcare decarbonization efforts. It demonstrates how guideline changes can be evaluated for environmental impact, but results are UK-specific and may not generalize.
👥 読者別の含意
🔬研究者:Methodology for combining cost and carbon footprint analysis in clinical pathways.
🏢実務担当者:Provides benchmark data for carbon footprint of oncology follow-up, useful for NHS sustainability teams.
🏛政策担当者:Demonstrates that guideline updates may not automatically reduce emissions; policy should explicitly target carbon reduction.
📄 Abstract（原文）
Abstract Cutaneous squamous cell carcinoma (SCC) follow-up incurs financial costs and carbon emissions through surveillance review appointments and associated care. This study aims to estimate the environmental and financial impact of SCC follow-up pathways, and to assess whether the updated BAD guidelines published in 2020 have influenced this impact. We analysed the care records of 50 patients with a histological diagnosis of SCC. We identified all dermatology healthcare touchpoints from the point of initial surgical diagnosis of SCC through to completion of their surveillance period. This included tumour staging, number and modalities of surveillance appointments, additional SCC treatments, and healthcare utilization (e.g. prescriptions, treatments) related or unrelated to their SCC diagnosis. Carbon footprint was estimated using published lifecycle analysis data or using the environmentally extended input–output analysis method. Overall, 62% of SCCs were of pathological tumour stage 1 (pT1), of which 61% were moderately or moderately poorly differentiated. The other 38% of SCCs were pT2, pT3 or not determined. Patients were stratified according to BAD risk categories: 10 of 50 low risk, 30 of 50 high risk, 3 of 50 very high risk, and 7 of 50 unclassified. The median (with 95% confidence interval) total financial cost and carbon footprint of SCC follow-up pathways, including additional related healthcare utilization, were £668 (95% CI 287–1323) and 80.9 kgCO2e (24.7–193) for low risk, £1111 (1006–1417) and 187 kgCO2e (151–244) for high risk, £1053 and 194 kgCO2e (CI not available due to small sample size) for very high risk, and £965 (0.0–1660) and 136 kgCO2e (0.0–245) for unclassified cases. Although combined median costs and carbon emissions were higher following the 2020 guideline update, no statistically significant overall difference was observed. This is the first real-world study to estimate the costs and carbon footprint of SCC follow-up pathways following surgical diagnosis. The 2020 BAD guidelines did not impact on these variables.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1093/bjd/ljag086.376first seen 2026-06-29 05:40:13 · last seen 2026-06-29 05:40:16
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。